The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...

The Francis Crick Institute’s flow cytometry core has shown at ELRIG 2025 how a heterogeneous fleet of spectral, mass and ...

Study links anxiety to 74% fewer natural killer cells—immune defenders against cancer and infections. Insomnia intensifies ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Study met its secondary endpoints and demonstrated improvement in biomarkers of collagen turnover, suggesting a resolution of fibrosis and repair of the alveolar basement membrane GRI-0621 ...

Analysis of the neutrophil proteome, i.e. the majority of all expressed proteins, can provide valuable insights into the functional dynamics of neutrophils under disease conditions. However, although ...

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...

GRI Bio (GRI) announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic ...

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.

At ELRIG 2025 Dr Barak Gilboa of Novo Nordisk unveiled a suite of AI-enabled approaches that turn brightfield microscopy from ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...